Antimicrobial Wound Care Dressings Market: Infection Control Economics Reshape Chronic Wound Protocols

Between 2020 and 2025 the category grew steadily as diabetic ulcer incidence climbed and hospitals widened antimicrobial protocols well beyond surgical wounds alone into chronic and pressure injury care. Growth was never explosive, but it rarely slowed either, compounding at 6.6 percent as silver dressings matured into a default standard of care across nearly every acute care setting tracked by MMA.
The base case assumes continued diabetic foot ulcer growth, expanding home health reimbursement coverage for advanced dressings, and a formulary shift toward PHMB and honey chemistries as silver resistance data accumulates across surveillance networks. Group purchasing organizations increasingly weight total cost of care over unit price, favoring dressings with published re-ulceration reduction data, a shift that sustains double-digit growth in the fastest chemistry segments through the full forecast window to 2036.
A bull scenario hinges on CMS extending hospital-acquired infection penalties into skilled nursing and home health settings, pulling forward antimicrobial dressing adoption across post-acute care broadly. The bear case is a reimbursement squeeze: bundled payment models could cap dressing spend per episode, forcing providers back toward cheaper iodine and basic silver formats regardless of published clinical evidence favoring premium chemistries.